On the other hand, Amin Ardestani et al. have recently identified Neratinib, an FDA-approved metastatic HER2-positive breast cancer drug that is also a potent MST1 inhibitor with 98% MST1 inhibition. This evidence concerns the gene ERBB2 and breast carcinoma.